Link-Asia International Medtech Group Ltd. (1143) AI Stock Analysis

• Market Cap: HK$87.47M
• Dividend Yield: N/A
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: -25.16%
• EPS Growth: -160.31%
• Country: HK
• Employees: 835
• Sector: Technology
• Sector Strength: 88
• Industry: Consumer Electronics
• EPS (TTM): -0.07
• Shares Outstanding: 224,289,180
• 10 Day Avg. Volume: 1,292,540
• 30 Day Avg. Volume: 1,091,788
• PEG Ratio: 0.29
• Price to Book (P/B): 0.13
• Price to Sales (P/S): 0.14
• P/FCF Ratio: -0.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: HK$0.38 ▲(0.00% Upside)

The score is primarily constrained by weak financial performance—declining revenues, volatile profitability, and inconsistent operating/free cash flow—partly offset by a comparatively steadier balance sheet. Technical signals are mixed without strong momentum, and valuation is penalized by a negative P/E with no dividend support.

Positive Factors

Diversified revenue streams and partnerships

Link-Asia's multi-channel revenue model and stated focus on partnerships and R&D collaborations create durable revenue diversification. Multiple sales routes and potential licensing reduce single-customer risk and support steadier cash conversion as new products scale over months to years.

Improving balance sheet equity ratio

An improving equity ratio and moderate leverage provide structural financial flexibility. This supports sustained investment in product development and capacity, lowers refinancing risk, and gives management room to fund strategic initiatives without immediate reliance on dilutive financing.

Stable gross margins and return to positive EBIT

Relatively stable gross margins indicate underlying product economics are resilient. The shift to positive EBIT in 2024 signals improving operational control and potential for durable profitability if revenue stabilization follows, supporting long-term margin sustainability.

Negative Factors

Sustained revenue decline

A persistent downward revenue trend erodes scale benefits and limits ability to leverage fixed-cost absorption. Continued top-line contraction over multiple years raises structural questions about market position, product competitiveness, and the viability of long-term growth plans.

Inconsistent operating cash flow

Repeated negative or inconsistent operating cash flow undermines the firm's ability to self-fund R&D, capex, and working capital. Over the medium term this forces reliance on external financing or asset sales, increasing refinancing risk and potentially diluting stakeholder returns.

Volatile profitability and sharp EPS decline

Large EPS deterioration and historically volatile net margins reduce earnings predictability and weaken capacity to invest consistently. Earnings instability complicates strategic planning and heightens execution risk for longer-term initiatives like new product rollouts and market expansion.

Link-Asia International Medtech Group Ltd. Business Overview & Revenue Model

Company Description

Link-Asia International MedTech Group Limited, an investment holding company, provides electronic manufacturing services (EMS) for the telecommunications, security, car electronics, home appliances, other consumer, and industrial electronic products. The company operates through four segments: EMS, Distribution of Communications Products, Securities and Other Assets Investment, and Real Estate Supply Chain Services. It is also involved in the trade of personal care products, business telephone systems, and telecommunication products; manufacture and sale of telecommunications and other products, and consumable electronic products; sale of audio equipment; and provision of consultancy services, as well as pre-pregnancy care and assisted reproductive services. In addition, the company offers equity investment and property agency services; and real estate advisory and purchase services. It operates in the People's Republic of China, the United States, Switzerland, France, Poland, the United Kingdom, Belgium, Russia, Thailand, Malaysia, Brazil, and internationally. The company was formerly known as Link-Asia International Co. Ltd. and changed its name to Link-Asia International MedTech Group Limited in December 2020. Link-Asia International MedTech Group Limited was founded in 1992 and is headquartered in Tsim Sha Tsui, Hong Kong.

How the Company Makes Money

Link-Asia International Medtech Group Ltd. generates revenue through multiple streams, primarily by selling its medical devices and technologies to healthcare providers, hospitals, and clinics. The company's revenue model is centered around direct sales, distribution agreements, and partnerships with healthcare institutions. Additionally, Link-Asia may engage in research and development collaborations, potentially leading to licensing agreements for new technologies. The company's financial performance can also be influenced by government contracts or grants, industry partnerships, and the overall demand for medical technology solutions in the markets it serves.

Link-Asia International Medtech Group Ltd. Financial Statement Overview

Summary

Overall financials are mixed: declining revenues and volatile profitability (income statement score 45) plus inconsistent and often negative operating cash flow (cash flow score 40) outweigh the comparatively steadier balance sheet with improving equity ratio and moderate leverage (balance sheet score 55).

Income Statement

Link-Asia International Medtech Group Ltd. has shown mixed results over recent years. The company experienced declining revenues with a negative growth trend from 2019 to 2024, particularly from 2021 to 2024. While gross profit margins remained relatively stable, net profit margins were volatile, indicating potential profitability issues. The positive EBIT margin in 2024 is a welcome improvement, although historical EBIT margins were negative.

Balance Sheet

The company's balance sheet reveals a stable equity position with a moderate debt-to-equity ratio, indicating a balanced capital structure. The equity ratio has improved over time, suggesting a strengthening financial foundation. However, the fluctuating total debt and liabilities pose potential risks to financial stability.

Cash Flow

Cash flow analysis indicates inconsistent cash flow management. Operating cash flow was negative in several years, impacting free cash flow generation. Though there was a significant improvement in free cash flow in 2022, the lack of consistent positive cash flow raises concerns about long-term liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	402.85M	479.32M	502.00M	529.25M	675.52M	595.02M
Gross Profit	90.89M	123.60M	136.87M	101.40M	144.89M	154.71M
EBITDA	14.14M	4.78M	40.49M	-14.06M	-4.54M	-116.52M
Net Income	-4.33M	8.04M	5.26M	-54.04M	-46.40M	-173.05M
Balance Sheet
Total Assets	875.18M	880.14M	776.42M	659.23M	677.98M	657.40M
Cash, Cash Equivalents and Short-Term Investments	331.35M	312.05M	271.57M	252.21M	146.80M	167.66M
Total Debt	94.77M	86.60M	26.75M	51.08M	61.20M	70.19M
Total Liabilities	343.00M	343.25M	287.69M	297.22M	311.98M	361.47M
Stockholders Equity	532.05M	536.53M	486.66M	359.86M	365.88M	295.46M
Cash Flow
Free Cash Flow	-47.91M	-75.67M	-132.09M	99.60M	-122.55M	-45.85M
Operating Cash Flow	-43.60M	-73.19M	-129.29M	107.55M	-100.45M	-15.04M
Investing Cash Flow	15.74M	49.83M	48.86M	2.13M	3.31M	-96.19M
Financing Cash Flow	55.49M	66.31M	101.84M	4.68M	74.19M	35.17M

Link-Asia International Medtech Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.38
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1143, the sentiment is Positive. The current price of 0.38 is above the 20-day moving average (MA) of 0.37, below the 50-day MA of 0.39, and below the 200-day MA of 0.38, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.74 is Neutral, neither overbought nor oversold. The STOCH value of 30.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1143.

Link-Asia International Medtech Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
0110	47 Neutral	HK$56.80M	-3.35	-216.50%	―	-35.77%	-1.06%
1143	45 Neutral	HK$87.47M	-20.21	-0.82%	―	-25.16%	-160.31%
8147	41 Neutral	HK$145.06M	28.63	―	―	21.86%	―
0328	40 Underperform	HK$59.57M	-0.45	―	―	-0.76%	93.44%

Link-Asia International Medtech Group Ltd. Corporate Events

China Energy Storage Technology Development Halts Trading Ahead of Takeover-Related Announcement

China Energy Storage Technology Development Limited has requested a halt in trading of its shares on the Main Board of the Hong Kong Stock Exchange, effective from 9:00 a.m. on 22 January 2026. The suspension comes ahead of an upcoming announcement under the Hong Kong Code on Takeovers and Mergers that will contain inside information, signaling a potential change in control or significant corporate transaction that could materially affect shareholders and the company’s future direction.

The most recent analyst rating on (HK:1143) stock is a Hold with a HK$0.37 price target. To see the full list of analyst forecasts on Link-Asia International Medtech Group Ltd. stock, see the HK:1143 Stock Forecast page.

China Energy Storage Technology Development Appoints New Co-Chairman

China Energy Storage Technology Development Limited, formerly known as Link-Asia International MedTech Group Ltd., has announced the appointment of Mr. Wang Wei as an executive Director and Co-Chairman, effective December 16, 2025. Mr. Wang, with extensive experience in management and internet technology cooperation, will focus on business expansion, sales, and marketing strategies, sharing responsibilities with Mr. Lin Dailian, the current Co-Chairman. This strategic appointment aims to enhance the company’s operational capabilities and market positioning.

The most recent analyst rating on (HK:1143) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Link-Asia International Medtech Group Ltd. stock, see the HK:1143 Stock Forecast page.

China Energy Storage Technology Development Limited Announces Board Composition

China Energy Storage Technology Development Limited, formerly known as Link-Asia International MedTech Group Ltd., has announced the composition of its board of directors. The board includes both executive and independent non-executive directors, with specific members assigned to the audit, remuneration, and nomination committees. This announcement provides clarity on the leadership structure and governance of the company, which could impact its strategic direction and operational oversight.

The most recent analyst rating on (HK:1143) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Link-Asia International Medtech Group Ltd. stock, see the HK:1143 Stock Forecast page.

China Energy Storage Technology Announces Change in Substantial Shareholder

China Energy Storage Technology Development Limited has announced a change in its substantial shareholder structure. Mr. Chen Dezhu, a major shareholder, has sold his 23.1% stake in the company to Fame Castle Enterprises Limited, which is owned by directors of the company’s subsidiaries. This transfer results in Fame Castle Enterprises becoming a substantial shareholder, holding 23.6% of the company’s shares, potentially impacting the company’s governance and strategic direction.

The most recent analyst rating on (HK:1143) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Link-Asia International Medtech Group Ltd. stock, see the HK:1143 Stock Forecast page.